Unknown

Dataset Information

0

New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.


ABSTRACT:

Background

Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a global health problem. Although new triple therapy (pegylated-interferon, ribavirin, and telaprevir/boceprevir) has recently been started and is expected to achieve a sustained virologic response of more than 70% in HCV genotype 1 patients, there are several problems to be resolved, including skin rash/ageusia and advanced anemia. Thus a new type of anti-HCV drug is still needed.

Methodology/principal findings

Recently developed HCV drug assay systems using HCV-RNA-replicating cells (e.g., HuH-7-derived OR6 and Li23-derived ORL8) were used to evaluate the anti-HCV activity of drug candidates. During the course of the evaluation of anti-HCV candidates, we unexpectedly found that two preclinical antimalarial drugs (N-89 and its derivative N-251) showed potent anti-HCV activities at tens of nanomolar concentrations irrespective of the cell lines and HCV strains of genotype 1b. We confirmed that replication of authentic HCV-RNA was inhibited by these drugs. Interestingly, however, this anti-HCV activity did not work for JFH-1 strain of genotype 2a. We demonstrated that HCV-RNA-replicating cells were cured by treatment with only N-89. A comparative time course assay using N-89 and interferon-? demonstrated that N-89-treated ORL8 cells had more rapid anti-HCV kinetics than did interferon-?-treated cells. This anti-HCV activity was largely canceled by vitamin E. In combination with interferon-? and/or ribavirin, N-89 or N-251 exhibited a synergistic inhibitory effect.

Conclusions/significance

We found that the preclinical antimalarial drugs N-89 and N-251 exhibited very fast and potent anti-HCV activities using cell-based HCV-RNA-replication assay systems. N-89 and N-251 may be useful as a new type of anti-HCV reagents when used singly or in combination with interferon and/or ribavirin.

SUBMITTER: Ueda Y 

PROVIDER: S-EPMC3758303 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.

Ueda Youki Y   Takeda Midori M   Mori Kyoko K   Dansako Hiromichi H   Wakita Takaji T   Kim Hye-Sook HS   Sato Akira A   Wataya Yusuke Y   Ikeda Masanori M   Kato Nobuyuki N  

PloS one 20130830 8


<h4>Background</h4>Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a global health problem. Although new triple therapy (pegylated-interferon, ribavirin, and telaprevir/boceprevir) has recently been started and is expected to achieve a sustained virologic response of more than 70% in HCV genotype 1 patients, there are several problems to be resolved, including skin rash/ageusia and advanced anemia. Thus a new type of anti-HCV drug is still needed.<h4>Methodology  ...[more]

Similar Datasets

| S-EPMC2941470 | biostudies-literature
| S-EPMC7477610 | biostudies-literature
| S-EPMC6158411 | biostudies-literature
| S-EPMC109725 | biostudies-literature
| S-EPMC4301123 | biostudies-other
| S-EPMC3160967 | biostudies-literature
| S-EPMC4291391 | biostudies-literature
| S-EPMC3233139 | biostudies-literature
| S-EPMC446091 | biostudies-literature
| S-EPMC2438262 | biostudies-literature